Summary  
ECOG-ACRIN Cancer Research Group’s Marketing/Clinical Education and Awareness staff will use approved language/images to help increase awareness of myeloMATCH treatment trial MM1OA-EA02 and support accrual efforts. The content below may be shared to the ECOG-ACRIN website, affiliated blogs, and social media channels. Links to these channels are included below. The content may also be shared by SWOG Cancer Research Network, which is leading the myeloMATCH master screening protocol, as well as staff at participating MM1OA-EA02 sites. This plan contains messaging tailored to patients and caregivers.

ECOG-ACRIN Website  
<https://www.ecog-acrin.org>

ECOG-ACRIN Blogs  
<https://blog-ecog-acrin.org>  
<https://advocacy-ecog-acrin.org>

Social Media Channels  
X/Twitter: <https://x.com/eaonc>  
Facebook: <https://www.facebook.com/eaonc/>   
LinkedIn: <https://www.linkedin.com/company/ecog-acrin-cancer-research-group/>  
Instagram: <https://www.instagram.com/ecog_acrin/>

Target Audience(s)  
The blood cancer community, including:

* Patients and survivors
* Caregivers
* Advocates
* Research, education, and advocacy organizations (e.g., Leukemia and Lymphoma Society, Leukemia Research Foundation)

Privacy/Confidentiality Considerations  
ECOG-ACRIN will make every possible effort to protect privacy and confidentiality by:

* Keeping social media post content general in nature and avoiding any specifics related to the trial or patients on the trial
* Refraining from direct engagement with individuals about their eligibility for trials
  + Instead, individuals will be directed to consult with their physician and/or the NCI’s Cancer Information Service
* Monitoring posts daily for inappropriate responses/interactions and flagging or removing as needed

General/Website Messaging

*The study below is part of the* [*myeloMATCH precision medicine initiative*](https://www.swog.org/myelomatch-overview) *for people with myeloid malignancies. The myeloMATCH Screening and Reassessment Protocol (MSRP) is led by the SWOG Cancer Research Network and* [*treatment trials*](https://www.swog.org/myelomatch-treatment-trials) *are led by the Alliance for Clinical Trials in Oncology, Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group, and SWOG. The entire initiative is sponsored by the National Cancer Institute through its National Clinical Trials Network.*

**MM1OA-EA02 Study**

*Venetoclax and Hypomethylating Agent (HMA) Treatment of Older and Unfit Adults with FLT3 Mutated AML*

*A myeloMATCH Treatment Study*

**Why consider participating in this study?**

* Research studies are an important way to test the effectiveness of new therapies and approaches for treating cancer.
* The usual approach (i.e., the standard treatment most people get for AML) is treatment with chemotherapy and other drugs. Sometimes, combinations of these treatments are used.
* The purpose of MM1OA-EA02 is to compare the usual treatment of the drugs azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax, and gilteritinib.
  + Researchers are trying to find out if adding the drug gilteritinib can lower the amount of leukemia in your body.

**What does this study involve?**

* This study is a part of the myeloMATCH Precision Medicine Trial, which you have previously agreed to participate in.
* If you are matched to the MM1OA-EA02 treatment study and choose to participate, you will be assigned by chance (randomized) to one of three study groups. Each study group will consist of approximately 49 participants.
  + **Group 1**: You will receive azacitidine (by injection into a vein in your arm or just beneath the skin) and venetoclax (a tablet you will take daily by mouth).
  + **Group 2**: You will receive azacitidine (via injection), venetoclax (via daily tablet), and gilteritinib (also a daily tablet you will take by mouth).
  + **Group 3**: You will receive azacitidine (via injection), venetoclax (via tablet), and the gilteritinib tablet, but starting on day 8 of the treatment cycle.
* Each cycle lasts 28 days and there will be a maximum of 24 cycles.
* After you finish MM1OA-EA02 study treatment, your doctor will monitor your condition for 10 years (every 3 months for the first 2 years, then every 6 months thereafter).

A diagram of a group of people

Description automatically generated

**Who will take part in this study?**

* Approximately 147 people diagnosed with AML will take part in MM1OA-EA02. You must be at least 60 years of age; however, individuals younger than 60 are eligible if your treating physician decides you would be better served by a treatment that includes azacitidine chemotherapy (instead of the more intensive cytarabine-based chemotherapy).
* You must also have a FLT3-ITD or D835 mutation, as required by the myeloMATCH Precision Medicine Trial.
* You can decide to stop taking part in this study at any time, even after you have enrolled.

**What are the costs of taking part in this study?**

* Just as if you were getting the usual care for your cancer, you and/or your insurance plan will need to pay for some or all of the costs of medical care you get as part of this study.
  + You/your insurance plan will **not** have to pay for venetoclax and gilteritinib while you take part in MM1OA-EA02.
  + Check with your insurance company for find out what they will pay for.
* Taking part in the study may mean that you need to make more visits to the clinic or hospital than if you were getting the usual approach to treat your cancer.
* You will not be paid for taking part in MM1OA-EA02.

**If you would like to know more**

* About the MM1OA-EA02 study, talk with your doctor, or:

--Visit [www.ecog-acrin.org](http://www.ecog-acrin.org) and search MM1OA-EA02, then select the link to MM1OA-EA02.

-- For information about medical facilities where the study is available, scroll down

the page to Locations and Contacts.

-- For more information on myeloMATCH, including a list of the myeloMATCH treatment trials, visit <https://www.swog.org/myelomatch-overview>.

-- Call the NCI Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

* About clinical trials:

--General cancer information: visit the NCI website at [www.cancer.gov](http://www.cancer.gov)

--Insurance coverage: visit [www.cancer.gov/clinicaltrials/learningabout/payingfor](http://www.cancer.gov/clinicaltrials/learningabout/payingfor)

* About ECOG-ACRIN:

--Visit [www.ecog-acrin.org](http://www.ecog-acrin.org)

--For a list of patient resources and links to patient advocacy groups, visit [https://ecog-](https://ecog-acrin.org/resources)

[acrin.org/patients/resources](https://ecog-acrin.org/resources)

Social Media Messaging

|  |  |
| --- | --- |
| **Facebook/LinkedIn** | **X/Twitter** |
| The MM1OA-EA02 clinical study is testing a new treatment approach for patients with acute myeloid leukemia who are age 60 or older. Learn more: <https://bit.ly/mm1oa-ea02-study> | The MM1OA-EA02 clinical study is testing a new treatment approach for patients with #AcuteMyeloidLeukemia who are age 60 or older. Learn more: <https://bit.ly/mm1oa-ea02-study> #AML #leukemia |
| Do you have acute myeloid leukemia (AML) and are age 60 or older? If so, you may be able to participate in this study of a potential new treatment. Learn more: <https://bit.ly/mm1oa-ea02-study> | Do you have #AcuteMyeloidLeukemia (#AML) and are age 60 or older? If so, you may be able to participate in this study of a potential new treatment. Learn more: <https://bit.ly/mm1oa-ea02-study> #leukemia #leusm |
| Clinical trial MM1OA-EA02, led by Dr. Jessica Altman of the Lurie Cancer Center, aims to improve results for older adults with acute myeloid leukemia (AML). Learn more: <https://bit.ly/ea3211-study> | #ClinicalTrial MM1OA-EA02, led by @jaltmanmd of @LurieCancer, aims to improve results for older adults with #AcuteMyeloidLeukemia (#AML). Learn more: <https://bit.ly/ea3211-study> #BloodCancer #leukemia |

**Hashtags:** #AcuteMyeloidLeukemia #AML #BloodCancer #leukemia #leusm

Images



A yellow ribbon on a blue background

Description automatically generated